GPT and neutropenia: The most common grade 3–4 treatment-related AEs (TRAEs) were lipase increase (5%), neutropenia (3%) and raised alanine transaminase (3%) for nivolumab, neutropenia (2.4%) and diarrhoea (1.4%) for pembrolizumab.